Intermittent versus continuous erlotinib with concomitant modified ‘XELOX’ (q3W) in first-line treatment of metastatic colorectal cancer (mCRC)
Invited conference paper presented and published in conference proceedings


Full Text

Other information
All Author(s) ListMA Buig Yue Brigette, CHAN Lam Stephen, HO Ming Wing, POON Annette Ngar, HUI Pun Edwin, DATTATRAY R D, WONG S C, CHAN Anthony Tak Cheung
Name of Conference35th ESMO Congress
Start Date of Conference08/10/2010
Country/Region of ConferenceItaly
Proceedings Title35th ESMO Congress
Year2010
Month10
Place of PublicationItaly
Pages1
LanguagesEnglish-United Kingdom
KeywordsXELOX

Last updated on 2018-23-01 at 18:12